An observational study in Multiple Sclerosis, sponsored by Biogen. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Biogen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Multiple Sclerosis by Biogen — 2 open to participants now, 4 under way, 1 of them phase 3. Multiple Sclerosis · Biogen.
Among the 127 studies in Multiple Sclerosis by Biogen, this one is the 28th largest by enrollment of the 48 observational ones that give a count, is one of 5 that started in 2023, is one of 48 observational ones, and was the 126th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 127 studies in Multiple Sclerosis by Biogen are open now, in 7 countries. Recruiting first, the newest first:
Biogen · Sites in United States, Australia, Germany and 4 more countries
Women only
Biogen
Ages 10–17
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 17 · Phase 3 29 · Phase 4 22
First in 1999; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 271 is above the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 110 across the 79 interventional studies, 355 across the 48 observational. Of the 119 that completed or were terminated, 36 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 127 studies in Multiple Sclerosis by Biogen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to estimate the incidence of Anti-Natalizumab Antibodies (ANAs) in the cohort of natalizumab-naïve and other MS monoclonal antibody (mAb)-naive participants who start receiving natalizumab subcutaneous (SC) injections. The secondary objectives of this study are to estimate the proportion of participants detected with ANAs when switched from natalizumab intravenous (IV) to natalizumab SC (natalizumab-experienced cohort); to evaluate serious adverse events (SAEs), including injection reactions and hypersensitivity reactions, by ANA status and to assess the proportion of participants who had MS relapse, by ANA status.
The study will collect data prospectively and retrospectively.
The study will include available EU MS registry participants.
Key Inclusion Criteria:
Key Exclusion Criteria :
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Per standard of care, participants with MS enrolled in selected MS registries, who are natalizumab-naïve and other MS mAb-therapy-naive will receive natalizumab 300 mg, SC injection according to decision of the treating physician.
Drug: Natalizumab
Per standard of care, participants with MS enrolled in selected MS registries, who have previously received natalizumab IV will be switched from natalizumab IV to SC administration to receive natalizumab 300 mg, SC injection according to decision of the treating physician.
Drug: Natalizumab
Administered as specified in the treatment arm.
Also known as: Tysabri
Percentage of Participants in Natalizumab-Naive and Other MS mAb-Naive Cohort who Start Taking Natalizumab Injections and Develop Anti-Natalizumab Antibodies (ANAs)
Time frame: Up to 1.75 years
Percentage of Participants in Natalizumab-Experienced Cohort who Switched From Natalizumab IV Infusion to SC Injection and Develop Anti-Natalizumab Antibodies (ANAs)
Time frame: Up to 1.75 years
Percentage of Participants With SAEs by Positive (Transient or Persistent) or Negative ANA Status
SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in permanent or significant damage to health or limitation of capabilities or is manifested as a congenital anomaly or birth defect in offspring, irrespective of the administered dose of the medicinal product.
Time frame: Up to 1.75 years
Percentage of Participants With MS Relapses by Positive (Transient or Persistent) or Negative ANA Status
Time frame: Up to 1.75 years
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Jun 2023 to primary completion in Oct 2026, 39 months.
Of 91 industry-sponsored observational studies under Multiple Sclerosis, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 75. This study's 39 months is below that.
Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.